Live Quote · NASDAQSCYXHealthcare· Medical - Pharmaceuticals

SCYNEXIS, Inc.

$4.43 4.73%(+$0.20)
TickerSpark Score
68/100
Solid
84
Valuation
40
Profitability
100
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SCYX research report →

52-Week Range11% of range
Low
$3.68
Current
$4.43
High
$10.48
Company Overviewwww.scynexis.com

About the company

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.

CEO
David Angulo
IPO
2014
Employees
18
HQ
Jersey City, NJ, US

Price Chart

-23.09% · this period
$9.44$6.62$3.80Jul 02Dec 31Jul 02
Valuation
Market Cap
$27.86M
P/E
-1.24
P/S
1.37
P/B
0.68
EV/EBITDA
0.28
Div Yield
0.00%
Profitability
Gross Margin
100.00%
Op Margin
-119.86%
Net Margin
-120.51%
ROE
-57.16%
ROIC
-39.18%
Growth & Income
Revenue
$20.60M · 449.95%
Net Income
$-8,609,000 · 59.56%
EPS
$-1.36 · 61.36%
Op Income
$-16,074,000
FCF YoY
78.00%
Performance & Tape
52W High
$10.48
52W Low
$3.68
50D MA
$5.62
200D MA
$6.05
Beta
1.06
Avg Volume
65.22K

Get TickerSpark's AI analysis on SCYX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 26, 26Tinmouth Brian Philippeother2,875
Jun 26, 26Tinmouth Brian Philippeother2,875
Jun 26, 26Macdonald Guyother2,875
Jun 26, 26Macdonald Guyother2,875
Jun 26, 26ANIDO ARMANDOother2,875
Jun 26, 26ANIDO ARMANDOother2,875
Jun 26, 26HASTINGS DAVID Cother2,875
Jun 26, 26HASTINGS DAVID Cother2,875
Jun 26, 26HANHAM ANNother2,875
Jun 26, 26HANHAM ANNother2,875
Coverage · SCYX

Our SCYX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on SCYX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate SCYX report →
Internal Compare

Similar companies

Peers in the same neighborhood.